Disrupting nicotine reinforcement: From cigarette to brain

Annals of the New York Academy of Sciences

Volumn 1141, Issue , 2008, Pages 233-256

  Rose, Jed E ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Center for Nicotine and Smoking Cessation Research   (United States)

Author keywords

Addiction; Agonist; Antagonist; Cigarette; Nicotine; Reinforcement; Reward; Tobacco

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; CANNABINOID RECEPTOR ANTAGONIST; CLONIDINE; GABAPENTIN; GLYCINE RECEPTOR ANTAGONIST; GW 468816; GW 469916; MECAMYLAMINE; NALMEFENE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NORTRIPTYLINE; OPIATE ANTAGONIST; PLACEBO; RIMONABANT; TOPIRAMATE; UNCLASSIFIED DRUG; VARENICLINE; VIGABATRIN;

AIRWAY DYNAMICS; ANTICHOLINERGIC SYNDROME; BLOOD BRAIN BARRIER; BLURRED VISION; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIZZINESS; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG OVERDOSE; HUMAN; INSOMNIA; LOZENGE; MENTAL DISEASE; MICTURITION DISORDER; MONOTHERAPY; NAUSEA; NEUROIMAGING; NICOTINE REPLACEMENT THERAPY; NONHUMAN; REINFORCEMENT; REVIEW; SENSORY NERVE CELL; SEXUAL DYSFUNCTION; SMOKING CESSATION; SUICIDAL IDEATION; SUICIDE; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

NICOTIANA TABACUM;

EID: 54949129115     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1441.019     Document Type: Review

References (165)

1. Ezzati, M. & A.D. Lopez. 2003. Estimates of global mortality attributable to smoking in 2000. Lancet 362 : 847 852.
2. DHHS. 1988. The Health Consequences of Smoking: Nicotine Addiction. U.S. Department of Health and Human Services, Office on Smoking and Health. Rockville, MD.
3. Kalivas, P.W. & N.D. Volkow. 2005. The neural basis of addiction: A pathology of motivation and choice. Am. J. Psychiatry 162 : 1403 1413.
4. Shiffman, S. et al. 2004. The nicotine dependence syndrome scale: A multidimensional measure of nicotine dependence. Nicotine Tob. Res. 6 : 327 348.
5. Rose, J.E. 2006. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl.) 184 : 274 285.
6. Dar, R. et al. 2007. Euphoriant effects of nicotine in smokers: Fact or artifact? Psychopharmacology (Berl.) 191 : 203 210.
7. Henningfield, J. et al. 1983. Cigarette smokers self-administer intravenous nicotine. Pharmacol. Biochem. Behav. 19 : 887 890.
8. Pomerleau, C.S. & O.F. Pomerleau. 1992. Euphoriant effects of nicotine in smokers. Psychopharmacology (Berl.) 108 : 460 465.
9. West, R. et al. 2006. Assessing DSM-IV nicotine withdrawal symptoms: A comparison and evaluation of five different scales. Psychopharmacology (Berl.) 184 : 619 627.
10. Fiore, M.C. 2000. Treating tobacco use and dependence: An introduction to the US Public Health Service Clinical Practice Guideline. Respir. Care 45 : 1196 1199.
11. Benowitz, N.L. & J.E. Henningfield. 1994. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N. Engl. J. Med. 331 : 123 125.
12. Gray, N. et al. 2005. Toward a comprehensive long term nicotine policy. Tob. Control 14 : 161 165.
13. Henningfield, J.E. et al. 1998. Reducing the addictiveness of cigarettes. Tob. Control 7 : 281 293.
14. Benowitz, N.L. et al. 1983. Smokers of low-yield cigarettes do not consume less nicotine. N. Engl. J. Med. 309 : 139 142.
15. Kozlowski, L.T. et al. 1994. Misuse of "light" cigarettes by means of vent blocking. J. Subst. Abuse 6 : 333 336.
16. Conkling, M.A. et al., inventors. 2002. Regulation of quinolate phosphoribosyl trasnferase expression. U.S. Patent 6,423,520.
17. Butschky, M.F. et al. 1995. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol. Biochem. Behav. 50 : 91 96.
18. Pickworth, W.B. et al. 1999. Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine Tob. Res. 1 : 357 364.
19. Rose, J. & F. Behm. 2004. Effects of low nicotine content cigarettes on smoke intake. Nicotine Tob. Res. 6 : 309 319.
20. Rose, J.E. et al. 2006. Pre-cessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob. Res. 8 : 89 101.
21. Rose, J.E. & F.M. Behm. 2004. Extinguishing the rewarding value of smoke cues: Pharmacological and behavioral treatments. Nicotine Tob. Res. 6 : 523 532.
22. Benowitz, N.L. et al. 2007. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol. Biomarkers Prev. 16 : 2479 2485.
23. Benowitz, N.L. et al. 2006. Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin. Pharmacol. Ther. 80 : 703 714.
24. Nil, R. & K. Battig. 1989. Separate effects of cigarette smoke yield and smoke taste on smoking behavior. Psychopharmacology 99 : 54 59.
25. Robinson, M.L. et al. 2000. Placebo cigarettes in smoking research. Exp. Clin. Psychopharmacol. 8 : 326 332.
26. Strasser, A.A. et al. 2007. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend. 86 : 294 300.
27. Donny, E.C. et al. 2007. Smoking in the absence of nicotine: Behavioral, subjective and physiological effects over 11 days. Addiction 102 : 324 334.
28. Heatherton, T.F. et al. 1991. The Fagerström test for nicotine dependence: A revision of the Fagerström tolerance questionnaire. Br. J. Addict. 86 : 1119 1127.
29. Hatsukami, D.K. 2007. Denicotinized cigarettes: Toxicity, dependence and cessation. Presented at the conference, Science and Future Directions for Nicotine Regulation. Rockville, MD, Nov. 29-30.
30. Becker, K.M. et al. 2008. A randomized trial of nicotine replacement in combination with reduced nicotine cigarettes for smoking cessation. Nicotine Tob. Res. 10 (7 1139 1148.
31. Rezaishiraz, H. et al. 2007. Treating smokers before the quit date: Can nicotine patches and denicotinized cigarettes reduce cravings? Nicotine Tob. Res. 9 : 1139 1146.
32. McClernon, F.J. et al. 2007. Selectively reduced responses to smoking cues in amygdala following extinction-based smoking cessation: Results of a preliminary functional magnetic resonance imaging study. Addict. Biol. 12 : 503 512.
33. Rose, J.E. et al. 2000. Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol. Biochem. Behav. 67 : 71 81.
34. Westman, E.C. et al. 1996. Dissociating the nicotine and airway sensory effects of smoking. Pharmacol. Biochem. Behav. 53 : 309 315.
35. Rose, J.E. et al. 1984. Subjective response to cigarette smoking following airway anesthetization. Addict. Behav. 9 : 211 215.
36. Rose, J.E. et al. 1985. Sensory blockade of smoking satisfaction. Pharmacol. Biochem. Behav. 23 : 289 293.
37. Westman, E.C. et al. 1995. Airway sensory replacement combined with nicotine replacement for smoking cessation. A randomized, placebo-controlled trial using a citric acid inhaler. Chest 107 : 1358 1364.
38. Lee, L.-Y. et al. 1993. Nicotine is responsible for the airway irritation evoked by cigarette smoke inhalation in men. J. Appl. Physiol. 75 : 1955 1961.
39. Rose, J.E. et al. 1999. Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacol. Biochem. Behav. 62 : 165 172.
40. Lee, L.Y. et al. 2007. Airway irritation and cough evoked by inhaled cigarette smoke: Role of neuronal nicotinic acetylcholine receptors. Pulm. Pharmacol. Ther. 20 : 355 364.
41. Lee, L.-Y. et al. 1989. Stimulation of vagal pulmonary C-fibers by a single breath of cigarette smoke in dogs. J. Appl. Physiol. 66 : 2032 2038.
42. Ginzel, K.H. & E. Eldred. 1977. Reflex depression of somatic motor activity from heart, lungs and carotid sinus. In Krogh Centenary Symposium on Respiratory Adaptation, Capillary Exchange and Reflex Mechanisms. A.S. Paintal & P. Gill-Kumar, Eds 358 395. Vallabhbai Patel Chest Institute, University of Delhi. Delhi, India.
43. Rennard, S.I. et al. 2006. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. Nicotine Tob. Res. 8 : 555 564.
44. Schneider, N.G. et al. 2001. The nicotine inhaler: Clinical pharmacokinetics and comparison with other nicotine treatments. Clin. Pharmacokinet. 40 : 661 684.
45. Bolliger, C.T. et al. 2000. Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety. BMJ 321 : 329 333.
46. Lunell, E. et al. 1996. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin. Pharmacol. Ther. 59 : 593 594.
47. Katz, I.M. et al. 2001. Factors affecting the deposition of aerosolized insulin. Diabetes Technol. Ther. 3 : 387 397.
48. Fowler, J.S. et al. 1996. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379 : 732 736.
49. Fowler, J.S. et al. 1996. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. USA 93 : 14065 14069.
50. Ding, Y.S. et al. 2006. Determination of 14 polycyclic aromatic hydrocarbons in mainstream smoke from U.S. brand and non-U.S. brand cigarettes. Environ. Sci. Technol. 40 : 1133 1138.
51. Benowitz, N.L. 1998. Summary: Risks and benefits of nicotine. In Nicotine Safety and Toxicity. N.L. Benowitz, Ed 185 194. Oxford University Press. New York, NY.
52. Stead, L. et al. 2008. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst RevCD000146.
53. West, R. et al. 2000. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl.) 149 : 198 202.
54. Jarvik, M.E. & K.M. Assil. 1988. Mecamylamine blocks the burning sensation of nicotine on the tongue. Chem. Senses. 13 : 213 217.
55. Rose, J.E. et al. 2001. Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacol. Biochem. Behav. 68 : 187 197.
56. West, R. et al. 2007. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl.) 197 : 371 377.
57. Russell, M.A.H. & C. Feyerabend. 1978. Cigarette smoking: A dependence on high-nicotine boli. Drug Metabol. Rev. 8 : 29 57.
58. Rose, J.E. et al. 1999. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implications for addiction. Drug Alcohol Depend. 56 : 99 107.
59. Brewer, B.G. et al. 2004. Short-term distribution of nicotine in the rat lung. Drug Alcohol Depend. 75 : 193 198.
60. Muhkin, A.G. et al. 2008. Comparison of brain nicotine accumulation after cigarette smoking in dependent and non-dependent smokers. Presented at the Annual Meeting of the Society of Nuclear Medicine. New Orleans, LA, June 14-18.
61. LeSage, M.G. et al. 2006. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl.) 184 : 409 416.
62. Pentel, P.R. et al. 2000. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65 : 191 198.
63. Vocci, F.J. & C.N. Chiang. 2001. Vaccines against nicotine: How effective are they likely to be in preventing smoking? CNS Drugs 15 : 505 514.
64. Hatsukami, D. et al. 2005. Results of a phase 2, multi-center, randomized, double-blinded, placebo-controlled, parallel-arm, dose comparison study to assess the immunogenicity and safety of 3′-aminomethylnicotine-P. aeruginosa R-exoprotein. A conjugate vaccine (NicVAX) administered to smokers. Presented at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco 38, Prague, Czech Republic, March 20-23.
65. Maurer, P. & M.F. Bachmann. 2007. Vaccination against nicotine: An emerging therapy for tobacco dependence. Expert. Opin. Investig. Drugs 16 : 1775 1783.
66. Rennard, S.I. et al. 2007. A randomized placebo-controlled trial of a conjugate nicotine vaccine (NicVAX®) in smokers who want to quit: 12 month results. Circulation 116 : II_844.
67. Heading, C.E. 2007. Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Curr. Opin. Investig. Drugs 8 : 71 77.
68. Changeux, J.P. et al. 1998. Brain nicotinic receptors: Structure and regulation, role in learning and reinforcement. Brain Res. Brain Res. Rev. 26 : 198 216.
69. Lindstrom, J. 1997. Nicotinic acetylcholine receptors in health and disease. Mol. Neurobiol. 15 : 193 222.
70. Cho, C.H. et al. 2005. Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J. Neurosci. 25 : 3712 3723.
71. Peters, M.J. & L.C. Morgan. 2002. The pharmacotherapy of smoking cessation. Med. J. Aust. 176 : 486 490.
72. Hughes, J.R. et al. 1984. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl.) 83 : 82 87.
73. Schneider, N.G. et al. 2008. Preferences among five nicotine treatments based on information versus sampling. Nicotine Tob. Res. 10 : 179 186.
74. Sweeney, C.T. et al. 2001. Combination nicotine replacement therapy for smoking cessation: Rationale, efficacy and tolerability. CNS Drugs 15 : 453 467.
75. Jasinski, D.R. & J.E. Henningfield. 1988. Conceptual basis of replacement therapies for chemical dependence. In Nicotine Replacement: A Critical Evaluation. O.F. Pomerleau & C.S. Pomerleau, Eds 13 34. Alan R. Liss, Inc. New York, NY.
76. Shiffman, S. et al. 2006. Analyzing milestones in smoking cessation: Illustration in a nicotine patch trial in adult smokers. J. Consult. Clin. Psychol. 74 : 276 285.
77. Shiffman, S. et al. 2006. Immediate hedonic response to smoking lapses: Relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl.) 184 : 608 618.
78. Rose, J.E. et al. 1994. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56 : 86 99.
79. Schuurmans, M.M. et al. 2004. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: A randomized controlled trial. Addiction 99 : 634 640.
80. Shiffman, S. & S.G. Ferguson. 2008. Nicotine patch therapy prior to quitting: A meta-analysis. Addiction 103 : 557 563.
81. Rose, J.E. et al. 2007. Pre-cessation treatment with nicotine patch. Significantly increases abstinence rates relative to conventional treatment. Presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco. Austin, TX, February 21-24.
82. Herrera, N. et al. 1995. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 108 : 447 451.
83. Allanby, K.D. & J.R. Trounce. 1957. Excretion of mecamylamine after intravenous and oral administration. BMJ 1 : 1219 1221.
84. Clarke, P.B.S. 1991. Nicotinic receptor blockade therapy and smoking cessation. In British Journal of Addiction, Vol. 86. West, R. & N.E. Grunberg, Eds 501 506. Carfax Publishing Company. London.
85. Lundahl, L.H. et al. 2000. Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol. Biochem. Behav. 66 : 637 643.
86. Nemeth-Coslett, R. et al. 1986. Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 88 : 420 425.
87. Pomerleau, C.S. et al. 1987. Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology 91 : 391 393.
88. Rose, J.E. et al. 1988. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharm. Biochem. Behav. 32 : 933 938.
89. Stolerman, I.P. et al. 1973. Influencing cigarette smoking with nicotine antagonists. Psychopharmacology 28 : 247 259.
90. Stolerman, I.P. 1986. Could nicotine antagonists be used in smoking cessation? Br. J. Addict. 81 : 47 53.
91. Rose, J.E. et al. 1998. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Exp. Clin. Psychopharmacol. 6 : 331 343.
92. Rose, J.E. & F.M. Behm. 2004. Extinguishing the rewarding value of smoke cues: Pharmacologic and behavioral treatments. Nicotine Tob. Res. 6 : 523 532.
93. Rose, J.E. et al. 1994. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56 : 86 99.
94. Rose, J.E. & E.C. Westman. 1999. Use of neostigmine in conjunction with nicotine/mecamylamine treatment for smoking cessation. Presented at the 5th Annual Meeting of the Society for Research on Nicotine and Tobacco. San Diego, CA, March 5-7.
95. Rose, J.E. & E.D. Levin. 1991. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. 41 : 219 226.
96. Glover, E.D. et al. 2007. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 102 : 795 802.
97. Coe, J.W. et al. 2005. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48 : 3474 3477.
98. Gonzales, D. et al. 2007. Comment: Oral varenicline for smoking cessation. Ann. Pharmacother. 41 : 720 721.
99. Jorenby, D.E. et al. 2006. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296 : 56 63.
100. Tonstad, S. et al. 2006. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 296 : 64 71.
101. Lam, S. & P.N. Patel. 2007. Varenicline: A selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol. Rev. 15 : 154 161.
102. Aubin, H.J. et al. 2008. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax doi
103. Oncken, C. et al. 2006. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 166 : 1571 1577.
104. Corrigall, W.A. et al. 1992. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl.) 107 : 285 289.
105. Di Chiara, G. 2000. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 393 : 295 314.
106. Pich, E.M. et al. 1997. Common neural substrates for the addictive properties of nicotine and cocaine. Science 275 : 83 86.
107. Balfour, D.J. et al. 2000. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav. Brain Res. 113 : 73 83.
108. Robinson, T.E. & K.C. Berridge. 2001. Incentive-sensitization and addiction. Addiction 96 : 103 114.
109. Wyvell, C.L. & K.C. Berridge. 2001. Incentive sensitization by previous amphetamine exposure: Increased cue-triggered "wanting" for sucrose reward. J. Neurosci. 21 : 7831 7840.
110. Brauer, L.H. et al. 2001. Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology (Berl.) 159 : 31 37.
111. Caskey, N.H. et al. 2002. Modulating tobacco smoking rates by dopaminergic stimulation and blockade. Nicotine Tob. Res. 4 : 259 266.
112. Dawe, S. et al. 1995. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl.) 117 : 110 115.
113. McClernon, F.J. et al. 2007. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology 33 : 2148 2157.
114. Rose, J.E. et al. 2007. Regional brain activity correlates of nicotine dependence. Neuropsychopharmacology 32 : 2441 2452.
115. Brody, A.L. et al. 2004. Smoking-induced ventral striatum dopamine release. Am. J. Psychiatry 161 : 1211 1218.
116. Pidoplichko, V.I. et al. 2004. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. Learn Mem. 11 : 60 69.
117. Dani, J.A. & M. De Biasi. 2001. Cellular mechanisms of nicotine addiction. Pharmacol. Biochem. Behav. 70 : 439 446.
118. Sofuoglu, M. et al. 2005. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl.) 181 : 504 510.
119. Dewey, S.L. et al. 1999. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31 : 76 86.
120. Schilstrom, B. et al. 2000. Putative role of presynaptic alpha7* nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38 : 375 383.
121. Heidbreder, C. 2005. Novel pharmacotherapeutic targets for the management of drug addiction. Eur. J. Pharmacol. 526 : 101 112.
122. Johnson, B.A. et al. 2005. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch. Intern. Med. 165 : 1600 1605.
123. Reid, M.S. et al. 2007. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology (Berl.) 192 : 147 158.
124. Sofuoglu, M. et al. 2006. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl.) 184 : 645 651.
125. Sood, A. et al. 2007. Gabapentin for smoking cessation: A preliminary investigation of efficacy. Nicotine Tob. Res. 9 : 291 298.
126. Mansvelder, H.D. 2005. Yin and yang of VTA opioid signaling. Focus on "both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons." J. Neurophysiol. 93 : 3046 3047.
127. Malin, D.H. et al. 1993. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl.) 112 : 339 342.
128. King, A.C. 2002. Role of naltrexone in initial smoking cessation: Preliminary findings. Alcohol Clin. Exp. Res. 26 : 1942 1944.
129. King, A. et al. 2006. Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine Tob. Res. 8 : 671 682.
130. Krishnan-Sarin, S. et al. 2003. Naltrexone and nicotine patch smoking cessation: A preliminary study. Nicotine Tob. Res. 5 : 851 857.
131. O'Malley, S.S. et al. 2006. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch. Intern. Med. 166 : 667 674.
132. Steinberg, B.A. & C.P. Cannon. 2007. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. Am. J. Cardiol. 100 : 27P 32P.
133. Ferry, L. & J.A. Johnston. 2003. Efficacy and safety of bupropion SR for smoking cessation: Data from clinical trials and five years of postmarketing experience. Int. J. Clin. Pract. 57 : 224 230.
134. Mays, K.L. et al. 2007. Nicotine and bupropion have similar effects on responding for reinforcing non-drug stimuli. Presented at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco. Austin, TX, February 21-24.
135. Mooney, M.E. & M. Sofuoglu. 2006. Bupropion for the treatment of nicotine withdrawal and craving. Expert. Rev. Neurother. 6 : 965 981.
136. Paterson, N.E. et al. 2007. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur. J. Neurosci. 25 : 3099 3108.
137. Damaj, M.I. et al. 2004. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 66 : 675 682.
138. Fryer, J.D. & R.J. Lukas. 1999. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 288 : 88 92.
139. Cousins, M.S. et al. 2001. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl.) 157 : 243 253.
140. Papke, R.L. et al. 2001. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 297 : 646 656.
141. Vaishnavi, S.N. et al. 2004. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry 55 : 320 322.
142. Hall, S.M. et al. 2004. Extended nortriptyline and psychological treatment for cigarette smoking. Am. J. Psychiatry 161 : 2100 2107.
143. Hall, S.M. et al. 2005. Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. J. Behav. Health Serv. Res. 32 : 381 392.
144. Hughes, J.R. et al. 2007. Antidepressants for smoking cessation. Cochrane Database Syst RevCD000031.
145. Whelan, A.M. & S.K. Davis. 1990. Doxepin in smoking cessation. DICP. 24 : 598 599.
146. Gumilar, F. et al. 2003. Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants. Neuropharmacology 45 : 964 976.
147. Wise, R.A. 1998. Drug-activation of brain reward pathways. Drug Alcohol Depend. 51 : 13 22.
148. Weiss, J.M. et al. 2005. Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galanin. Neuropeptides 39 : 281 287.
149. Klimek, V. et al. 2001. Effects of long-term cigarette smoking on the human locus coeruleus. Arch. Gen. Psychiatry 58 : 821 827.
150. Svensson, T.H. et al. 1990. Effect of nicotine on dynamic function of brain catecholamine neurons. Ciba Found. Symp. 152 : 169 180 discussion 180-5.
151. Tung, C.S. et al. 1989. Peripheral induction of burst firing in locus coeruleus neurons by nicotine mediated via excitatory amino acids. Synapse 4 : 313 318.
152. Gourlay, S.G. et al. 2004. Clonidine for smoking cessation. Cochrane Database Syst RevCD000058.
153. Fagerstrom, K.O. 1991. Towards better diagnoses and more individual treatment of tobacco dependence. Br. J. Addict. 86 : 543 547.
154. Uhl, G.R. et al. 2007. Molecular genetics of nicotine dependence and abstinence: Whole genome association using 520,000 SNPs. BMC Genet. 8 : 10.
155. Uhl, G.R. et al. 2008. Molecular genetics of successful smoking cessation: Convergent genome-wide association results. Arch. Gen. Psychiatry 65 : 683 693.
156. Breslau, N. et al. 2004. Psychiatric disorders and stages of smoking. Biol. Psychiatry 55 : 69 76.
157. Hughes, J.R. et al. 1986. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 143 : 993 997.
158. Lasser, K. et al. 2000. Smoking and mental illness: A population-based prevalence study. JAMA 284 : 2606 2610.
159. Hughes, J.R. 1999. Comorbidity and smoking. Nicotine Tob. Res. 1 (Suppl 2 S149 S152 discussion S165-166.
160. Kollins, S.H. et al. 2005. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch. Gen. Psychiatry 62 : 1142 1147.
161. Adler, L.E. et al. 1992. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 32 : 607 616.
162. McClernon, F.J. et al. 2006. Transdermal nicotine attenuates depression symptoms in nonsmokers: A double-blind, placebo-controlled trial. Psychopharmacology (Berl.) 189 : 125 133.
163. Buckley, T.C. et al. 2007. The effect of nicotine and attention allocation on physiological and self-report measures of induced anxiety in PTSD: A double-blind placebo-controlled trial. Exp. Clin. Psychopharmacol. 15 : 154 164.
164. Conners, C.K. et al. 1996. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol. Bull. 32 : 67 73.
165. Hymowitz, N. & H. Eckholdt. 1996. Effects of a 2.5-mg silver acetate lozenge on initial and long-term smoking cessation. Prev. Med. 25 : 537 546.